ASX - By Stock
|
BOT |
Re:
Ann: Letter to Shareholders - Notice of General Meeting
|
|
Blackcat13
|
26 |
11K |
1 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
26
|
11K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
Blackcat13
|
1.5K |
506K |
15 |
05/06/22 |
05/06/22 |
ASX - By Stock
|
1.5K
|
506K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
rurenga
|
|
Blackcat13
|
62 |
22K |
28 |
27/03/22 |
27/03/22 |
ASX - By Stock
|
62
|
22K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Who is ready for that 55% surge?
|
|
Blackcat13
|
44 |
11K |
2 |
05/01/22 |
05/01/22 |
ASX - By Stock
|
44
|
11K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Myocarditis and COVID vaccines
|
|
Blackcat13
|
54 |
19K |
3 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
54
|
19K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
Blackcat13
|
1.6K |
464K |
7 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
1.6K
|
464K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Deadline for Novartis
|
|
Blackcat13
|
429 |
130K |
2 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
429
|
130K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Deadline for Novartis
|
|
Blackcat13
|
429 |
130K |
4 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
429
|
130K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Deadline for Novartis
|
|
Blackcat13
|
429 |
130K |
4 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
429
|
130K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Deadline for Novartis
|
|
Blackcat13
|
429 |
130K |
2 |
26/03/21 |
26/03/21 |
ASX - By Stock
|
429
|
130K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
Blackcat13
|
49 |
13K |
4 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
49
|
13K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
Blackcat13
|
183 |
94K |
13 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
94K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Guess the opening price - if ARDS halted due supreme efficacy
|
|
Blackcat13
|
416 |
132K |
3 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
416
|
132K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
Blackcat13
|
576 |
234K |
4 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
234K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
Blackcat13
|
576 |
234K |
6 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
234K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB-CYP- Can we compare them?
|
|
Blackcat13
|
22 |
8.6K |
6 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
22
|
8.6K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB-CYP- Can we compare them?
|
|
Blackcat13
|
22 |
8.6K |
4 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
22
|
8.6K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Blackcat13
|
13K |
5.0M |
2 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
13K
|
5.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MSB-CYP- Can we compare them?
|
|
Blackcat13
|
22 |
8.6K |
28 |
22/08/20 |
22/08/20 |
ASX - By Stock
|
22
|
8.6K
|
28
|
|
ASX - By Stock
|
BCC |
Re:
Ann: Appendix 4C June Quarter 2020
|
|
Blackcat13
|
8 |
3.2K |
1 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
8
|
3.2K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
Blackcat13
|
854 |
431K |
10 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
Blackcat13
|
854 |
431K |
2 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
|
|
Blackcat13
|
854 |
431K |
15 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
854
|
431K
|
15
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
27 |
27/07/20 |
27/07/20 |
ASX - By Stock
|
23K
|
13M
|
27
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
10 |
19/07/20 |
19/07/20 |
ASX - By Stock
|
23K
|
13M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
1 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
1.0K
|
492K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
0 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
1.0K
|
492K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
10 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
1.0K
|
492K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
10 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
1.0K
|
492K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
11 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
1.0K
|
492K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
13 |
25/06/20 |
25/06/20 |
ASX - By Stock
|
1.0K
|
492K
|
13
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
7 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
2 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Blackcat13
|
9.9K |
2.9M |
6 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
9.9K
|
2.9M
|
6
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
14 |
19/06/20 |
19/06/20 |
ASX - By Stock
|
23K
|
13M
|
14
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Blackcat13
|
9.9K |
2.9M |
9 |
19/06/20 |
19/06/20 |
ASX - By Stock
|
9.9K
|
2.9M
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
0 |
18/06/20 |
18/06/20 |
ASX - By Stock
|
23K
|
13M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
2 |
18/06/20 |
18/06/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
28 |
17/06/20 |
17/06/20 |
ASX - By Stock
|
23K
|
13M
|
28
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
7 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
13 |
13/06/20 |
13/06/20 |
ASX - By Stock
|
23K
|
13M
|
13
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
4 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
19 |
20/05/20 |
20/05/20 |
ASX - By Stock
|
1.0K
|
492K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Blackcat13
|
1.0K |
492K |
7 |
20/05/20 |
20/05/20 |
ASX - By Stock
|
1.0K
|
492K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Capital raising
|
|
Blackcat13
|
197 |
71K |
12 |
18/05/20 |
18/05/20 |
ASX - By Stock
|
197
|
71K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Blackcat13
|
933 |
436K |
6 |
12/05/20 |
12/05/20 |
ASX - By Stock
|
933
|
436K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Blackcat13
|
933 |
436K |
18 |
12/05/20 |
12/05/20 |
ASX - By Stock
|
933
|
436K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Blackcat13
|
933 |
436K |
36 |
12/05/20 |
12/05/20 |
ASX - By Stock
|
933
|
436K
|
36
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
4 |
06/05/20 |
06/05/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Blackcat13
|
23K |
13M |
11 |
06/05/20 |
06/05/20 |
ASX - By Stock
|
23K
|
13M
|
11
|
|